Evolving paradigms in the pathogenesis of IBD.
The pathogenesis of all immune-mediated inflammatory diseases has been carefully studied over the past several decades, but it is only recently that we have come to appreciate common pathways and genes. This is especially true for the inflammatory bowel diseases (IBD) Crohn's disease and ulcerative colitis, where a keener appreciation of the contributions of genetics, environment, and immune response have been dissected. In fact, in many ways, IBD has become the model for studying such disorders. The complex nature of interactions is continuing to be defined, and novel therapies targeting defects in these interactions have been developed and are being tested in the clinic. The era of bench to bedside has finally matured, and cures for debilitating diseases are now in sight. This review describes our current state of knowledge of each component of IBD pathogenesis. What has evolved is a clearer picture and novel targets for therapy.
Mayer
Lloyd
L
Immunology Institute, Mount Sinai Medical Center, 1425 Madison Avenue, New York, NY 10029, USA. lloyd.mayer@mssm.edu
D056704:Adaptive Immunity; D000818:Animals; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D003424:Crohn Disease / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D016503:Drug Delivery Systems; D020022:Genetic Predisposition to Disease; D006801:Humans; D007113:Immunity, Innate